Patents by Inventor Kelly Helen Tabor

Kelly Helen Tabor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatocyte growth factor receptor antagonists and uses thereof
    Patent number: 6214344
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Grant
    Filed: January 14, 1998
    Date of Patent: April 10, 2001
    Assignee: Genetech, Inc.
    Inventors: Ralph H. Schwall, Kelly Helen Tabor
  • Hepatocyte growth factor receptor antagonist antibodies and uses thereof
    Patent number: 5686292
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: November 11, 1997
    Assignee: Genentech, Inc.
    Inventors: Ralph H. Schwall, Kelly Helen Tabor
  • Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
    Patent number: 5646036
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 8, 1997
    Assignee: Genentech, Inc.
    Inventors: Ralph H. Schwall, Kelly Helen Tabor